Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals

Kunal Dhiman; Victor L. Villemagne; Christopher Fowler; Pierrick Bourgeat; Qiao Xin Li; Steven Collins; Christopher C. Rowe; Colin L. Masters; David Ames; Kaj Blennow; Henrik Zetterberg; Ralph N. Martins; Veer Gupta

doi:10.1002/dad2.12377

Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals

Kunal Dhiman, Victor L. Villemagne, Christopher Fowler, Pierrick Bourgeat, Qiao Xin Li, Steven Collins, Christopher C. Rowe, Colin L. Masters, David Ames, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins, Veer Gupta^*

^*Corresponding author for this work

Macquarie Medical School

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

45 Downloads (Pure)

Abstract

Introduction: Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and the likelihood/risk of developing amyloidopathy in cognitively healthy individuals. Methods: FABP3 levels were measured in CSF samples of cognitively healthy participants, > 60 years of age (n = 142), from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results: FABP3 levels were positively associated with baseline brain amyloid beta (Aβ) load as measured by standardized uptake value ratio (SUVR, standardized β = 0.22, P =.009) and predicted the change in brain Aβ load (standardized β = 0.32, P =.004). Higher levels of CSF FABP3 (above median) were associated with a likelihood of amyloidopathy (odds ratio [OR] 2.28, 95% confidence interval [CI] 1.12 to 4.65, P =.023). Discussion: These results support inclusion of CSF FABP3 as a biomarker in risk-prediction models of AD.

Original language	English
Article number	e12377
Pages (from-to)	1-8
Number of pages	8
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	14
Issue number	1
DOIs	https://doi.org/10.1002/dad2.12377
Publication status	Published - 2022

Bibliographical note

Copyright the Author(s) 2022. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

Alzheimer's disease
amyloid
early diagnosis
risk prediction
screening

Access to Document

10.1002/dad2.12377Licence: CC BY-NC

Publisher version (open access)Final published version, 248 KBLicence: CC BY-NC

Cite this

Dhiman, K., Villemagne, V. L., Fowler, C., Bourgeat, P., Li, Q. X., Collins, S., Rowe, C. C., Masters, C. L., Ames, D., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. (2022). Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 14(1), 1-8. Article e12377. https://doi.org/10.1002/dad2.12377

@article{2f033a8178fc44e8913d17fef7c0e8e2,

title = "Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals",

abstract = "Introduction: Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and the likelihood/risk of developing amyloidopathy in cognitively healthy individuals. Methods: FABP3 levels were measured in CSF samples of cognitively healthy participants, > 60 years of age (n = 142), from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results: FABP3 levels were positively associated with baseline brain amyloid beta (Aβ) load as measured by standardized uptake value ratio (SUVR, standardized β = 0.22, P =.009) and predicted the change in brain Aβ load (standardized β = 0.32, P =.004). Higher levels of CSF FABP3 (above median) were associated with a likelihood of amyloidopathy (odds ratio [OR] 2.28, 95% confidence interval [CI] 1.12 to 4.65, P =.023). Discussion: These results support inclusion of CSF FABP3 as a biomarker in risk-prediction models of AD.",

keywords = "Alzheimer's disease, amyloid, early diagnosis, risk prediction, screening",

author = "Kunal Dhiman and Villemagne, {Victor L.} and Christopher Fowler and Pierrick Bourgeat and Li, {Qiao Xin} and Steven Collins and Rowe, {Christopher C.} and Masters, {Colin L.} and David Ames and Kaj Blennow and Henrik Zetterberg and Martins, {Ralph N.} and Veer Gupta",

note = "Copyright the Author(s) 2022. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2022",

doi = "10.1002/dad2.12377",

language = "English",

volume = "14",

pages = "1--8",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier",

number = "1",

}

Dhiman, K, Villemagne, VL, Fowler, C, Bourgeat, P, Li, QX, Collins, S, Rowe, CC, Masters, CL, Ames, D, Blennow, K, Zetterberg, H, Martins, RN & Gupta, V 2022, 'Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 14, no. 1, e12377, pp. 1-8. https://doi.org/10.1002/dad2.12377

Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. / Dhiman, Kunal; Villemagne, Victor L.; Fowler, Christopher et al.
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, No. 1, e12377, 2022, p. 1-8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals

AU - Dhiman, Kunal

AU - Villemagne, Victor L.

AU - Fowler, Christopher

AU - Bourgeat, Pierrick

AU - Li, Qiao Xin

AU - Collins, Steven

AU - Rowe, Christopher C.

AU - Masters, Colin L.

AU - Ames, David

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Martins, Ralph N.

AU - Gupta, Veer

N1 - Copyright the Author(s) 2022. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2022

Y1 - 2022

N2 - Introduction: Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and the likelihood/risk of developing amyloidopathy in cognitively healthy individuals. Methods: FABP3 levels were measured in CSF samples of cognitively healthy participants, > 60 years of age (n = 142), from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results: FABP3 levels were positively associated with baseline brain amyloid beta (Aβ) load as measured by standardized uptake value ratio (SUVR, standardized β = 0.22, P =.009) and predicted the change in brain Aβ load (standardized β = 0.32, P =.004). Higher levels of CSF FABP3 (above median) were associated with a likelihood of amyloidopathy (odds ratio [OR] 2.28, 95% confidence interval [CI] 1.12 to 4.65, P =.023). Discussion: These results support inclusion of CSF FABP3 as a biomarker in risk-prediction models of AD.

AB - Introduction: Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and the likelihood/risk of developing amyloidopathy in cognitively healthy individuals. Methods: FABP3 levels were measured in CSF samples of cognitively healthy participants, > 60 years of age (n = 142), from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results: FABP3 levels were positively associated with baseline brain amyloid beta (Aβ) load as measured by standardized uptake value ratio (SUVR, standardized β = 0.22, P =.009) and predicted the change in brain Aβ load (standardized β = 0.32, P =.004). Higher levels of CSF FABP3 (above median) were associated with a likelihood of amyloidopathy (odds ratio [OR] 2.28, 95% confidence interval [CI] 1.12 to 4.65, P =.023). Discussion: These results support inclusion of CSF FABP3 as a biomarker in risk-prediction models of AD.

KW - Alzheimer's disease

KW - amyloid

KW - early diagnosis

KW - risk prediction

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=85145041948&partnerID=8YFLogxK

U2 - 10.1002/dad2.12377

DO - 10.1002/dad2.12377

M3 - Article

C2 - 36479019

AN - SCOPUS:85145041948

SN - 2352-8729

VL - 14

SP - 1

EP - 8

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

IS - 1

M1 - e12377

ER -

Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this